1.
Islam MT, Ali ES, Uddin SJ, et al. Phytol: A review of biomedical activities. Food Chem Toxicol. 2018;121:82-94. doi:10.1016/j.fct.2018.08.032.
1.
Hoover P, Der E, Berthier CC, et al. Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020;72(2):233-242. doi:10.1002/acr.24066.
1.
Hoover CA, Slattery M, Marsh AG. A functional approach to transcriptome profiling: linking gene expression patterns to metabolites that matter. Mar Biotechnol (NY). 2007;9(4):411-9. doi:10.1007/s10126-007-9008-2.
1.
Steele FR. Big Pharma’s Commedia. Cell. 2005;123(6):971-3. doi:10.1016/j.cell.2005.11.033.
1.
Hyman SE. Time for new schizophrenia Rx. Science. 2014;343(6176):1177. doi:10.1126/science.1252603.
1.
de Souza A, Bittker JA, Lahr DL, et al. An Overview of the Challenges in Designing, Integrating, and Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and Disciplines. J Biomol Screen. 2014;19(5):614-27. doi:10.1177/1087057113517139.
1.
Pardes H, Manton KG, Lander ES, Tolley HD, Ullian AD, Palmer H. Effects of medical research on health care and economy. Science. 1999;283(5398):36-7.
1.
Schreiber SL. Organic chemistry: Molecular diversity by design. Nature. 2009;457(7226):153-4. doi:10.1038/457153a.
1.
Schreiber SL. Stuart Schreiber: biology from a chemist’s perspective. Interview by Joanna Owens. Drug Discov Today. 2004;9(7):299-303. doi:10.1016/S1359-6446(04)03063-6.